维普中文期刊产品整合服务
18篇 您的检索式:作者名="Edeline E"
    题名 作者 年代 出处 被引量
1Cementoplasty for painful bone metastases: a series of 42 cases 显示文摘Botton E Edeline J Rolland Y 2012Medical Ontology2012,29,2:1
2Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modi- fied RECIST in patients treated with sorafenib for hepatocellular carci- noma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
3Comparison of tumor res-ponse by response evaluation criteria in solid tumors (RECIST)and modified RECIST in patients treated with sorafenib forhepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,:1
4Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma 显示文摘EDELINE J BOUCHER E ROLLAND Y 2012Cancer2012,118,1:1
5Comparison of tumor re- sponse by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocel- lular carcinoma 显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
6Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
7Comparison of tumor re- sponse by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocel- lular carcinoma 显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
8Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
9Comparison of tu- mor response by response evaluation criteria in solid tu- mors (RECIST) and modified RECIST in patients treated with sorafeoib for hepatocellular carcinoma 显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
10Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
11Comparison of tumor response by response Evaluation criteria in solid tumors (RECIST)and modified RECIST in patients treated With sorafenib for hepatocellular carcinoma显示文摘Edeline J Roucher E Rolland Y 2012Cancer2012,118,:1
12Is salinity choice related to growth in juvenile eel AnguiUa Aaguilla 显示文摘Edeline E Elie P 2004Cybium2004,28,1:1
13Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
14Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
15Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
16Comparison of tumor response by Response Evaluation Criteria in Solid Tumors ( RE- CIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma 显示文摘Edeline J Boncher E Vaul6on E 2012Cancer2012,118,1:1
17Comparison of tumor re- sponse by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenih for hepa- tocellular careinoma显示文摘Edeline J Boueher E Rolland Y 2012Cancer2012,,:1
18Comparison of tumor response by response evaluation criteria in solid tumors (RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma显示文摘Edeline J Boucher E Rolland Y 2012Cancer2012,118,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费